RBC Capital Upgrades Amgen to Outperform, Raises Price Target to $300
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza upgraded Amgen (NASDAQ:AMGN) from Sector Perform to Outperform and increased the price target from $256 to $300.
December 12, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amgen's stock rating was upgraded by RBC Capital from Sector Perform to Outperform, with a price target increase from $256 to $300.
Upgrades by analysts, especially from reputable firms like RBC Capital, can lead to increased investor confidence and a potential short-term rise in the stock price. The substantial increase in the price target from $256 to $300 indicates a strong conviction in the company's future performance, which may positively influence the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100